Skip to main content
Top
Published in: Diabetologia 4/2009

Open Access 01-04-2009 | Article

Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study

Authors: J. W. M. Nin, I. Ferreira, C. G. Schalkwijk, M. H. Prins, N. Chaturvedi, J. H. Fuller, C. D. A. Stehouwer, EURODIAB Prospective Complications Study Group

Published in: Diabetologia | Issue 4/2009

Login to get access

Abstract

Aims/hypothesis

Plasma soluble receptor for AGE (sRAGE) may reflect the activity of the AGE–RAGE axis, which has been proposed as a potential mechanism linking hyperglycaemia to vascular complications in diabetes. We have therefore investigated: (1) whether sRAGE is associated with greater prevalence of cardiovascular disease (CVD) and microvascular complications in type 1 diabetic individuals; and (2) the extent to which any such associations are explained by markers of endothelial and renal dysfunction and inflammation.

Methods

The study included 477 individuals (234 women; mean age 42 ± 10 [SD] years) from the EURODIAB Prospective Complications Study. We used linear regression analyses to investigate the differences in sRAGE levels between individuals with and without vascular complications. All analyses were adjusted for age, sex, HbA1c, duration of diabetes and other risk factors.

Results

Individuals with CVD (n = 116) had higher levels of sRAGE than those without CVD or any microvascular complications (n = 178): β = 0.15 (95% CI 0.04–0.27). Further adjustments for markers of endothelial (β = 0.13 [0.02–0.24]) and renal dysfunction (β = 0.10 [−0.01, 0.20]) and inflammation (β = 0.12 [0.01–0.23]) attenuated these differences; altogether these variables explained about 50% of the association between sRAGE and prevalent CVD. sRAGE levels tended to be higher in the presence and across the levels of severity of albuminuria (p for trend = 0.087) and retinopathy (p for trend = 0.057); adjustments for endothelial and renal dysfunction and inflammation also attenuated these differences.

Conclusions/interpretation

sRAGE is associated with greater prevalence of CVD in type 1 diabetic individuals, and these associations may be partly explained by endothelial and renal dysfunction and low-grade inflammation.
Appendix
Available only for authorised users
Literature
1.
go back to reference Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM (2006) High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 29:798–804PubMedCrossRef Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, Colhoun HM (2006) High risk of cardiovascular disease in patients with type 1 diabetes in the U.K.: a cohort study using the general practice research database. Diabetes Care 29:798–804PubMedCrossRef
2.
go back to reference Laing SP, Swerdlow AJ, Slater SD et al (2003) Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46:760–765PubMedCrossRef Laing SP, Swerdlow AJ, Slater SD et al (2003) Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 46:760–765PubMedCrossRef
3.
go back to reference Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef
4.
go back to reference Yonekura H, Yamamoto Y, Sakurai S et al (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097–1109PubMedCrossRef Yonekura H, Yamamoto Y, Sakurai S et al (2003) Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370:1097–1109PubMedCrossRef
5.
go back to reference Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J (2003) Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing? Biochim Biophys Acta 1630:1–6PubMed Schlueter C, Hauke S, Flohr AM, Rogalla P, Bullerdiek J (2003) Tissue-specific expression patterns of the RAGE receptor and its soluble forms—a result of regulated alternative splicing? Biochim Biophys Acta 1630:1–6PubMed
6.
go back to reference Hudson BI, Carter AM, Harja E et al (2008) Identification, classification, and expression of RAGE gene splice variants. FASEB J 22:1572–1580PubMedCrossRef Hudson BI, Carter AM, Harja E et al (2008) Identification, classification, and expression of RAGE gene splice variants. FASEB J 22:1572–1580PubMedCrossRef
7.
go back to reference Raucci A, Cugusi S, Antonelli A et al (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22:3716–3727PubMedCrossRef Raucci A, Cugusi S, Antonelli A et al (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22:3716–3727PubMedCrossRef
8.
go back to reference Kislinger T, Fu C, Huber B et al (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740–31749PubMedCrossRef Kislinger T, Fu C, Huber B et al (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740–31749PubMedCrossRef
9.
go back to reference Harja E, Bu DX, Hudson BI et al (2008) Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE−/− mice. J Clin Invest 118:183–194PubMedCrossRef Harja E, Bu DX, Hudson BI et al (2008) Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE−/− mice. J Clin Invest 118:183–194PubMedCrossRef
10.
go back to reference Basta G, Lazzerini G, Massaro M et al (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105:816–822PubMedCrossRef Basta G, Lazzerini G, Massaro M et al (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105:816–822PubMedCrossRef
11.
go back to reference Hofmann MA, Drury S, Fu C et al (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889–901PubMedCrossRef Hofmann MA, Drury S, Fu C et al (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889–901PubMedCrossRef
12.
go back to reference Wendt TM, Tanji N, Guo J et al (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162:1123–1137PubMed Wendt TM, Tanji N, Guo J et al (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 162:1123–1137PubMed
13.
go back to reference Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ (2006) Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49:2756–2762PubMedCrossRef Tan KC, Shiu SW, Chow WS, Leng L, Bucala R, Betteridge DJ (2006) Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49:2756–2762PubMedCrossRef
14.
go back to reference Nakamura K, Yamagishi S, Adachi H et al (2008) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 76:52–56PubMedCrossRef Nakamura K, Yamagishi S, Adachi H et al (2008) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc Res 76:52–56PubMedCrossRef
15.
go back to reference Nakamura K, Yamagishi S, Adachi H et al (2007) Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 23:368–371PubMedCrossRef Nakamura K, Yamagishi S, Adachi H et al (2007) Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab Res Rev 23:368–371PubMedCrossRef
16.
go back to reference Humpert PM, Djuric Z, Kopf S et al (2007) Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6:9PubMedCrossRef Humpert PM, Djuric Z, Kopf S et al (2007) Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes. Cardiovasc Diabetol 6:9PubMedCrossRef
17.
go back to reference Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL (2005) Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 51:1749–1750PubMedCrossRef Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL (2005) Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 1 diabetes. Clin Chem 51:1749–1750PubMedCrossRef
18.
go back to reference Koyama H, Shoji T, Yokoyama H et al (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25:2587–2593PubMedCrossRef Koyama H, Shoji T, Yokoyama H et al (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25:2587–2593PubMedCrossRef
19.
go back to reference Katakami N, Matsuhisa M, Kaneto H et al (2005) Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28:2716–2721PubMedCrossRef Katakami N, Matsuhisa M, Kaneto H et al (2005) Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28:2716–2721PubMedCrossRef
20.
go back to reference Katakami N, Matsuhisa M, Kaneto H et al (2008) Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res 5:190–197PubMedCrossRef Katakami N, Matsuhisa M, Kaneto H et al (2008) Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res 5:190–197PubMedCrossRef
21.
go back to reference Katakami N, Matsuhisa M, Kaneto H et al (2009) Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis doi:101016/jatherosclerosis200808026 Katakami N, Matsuhisa M, Kaneto H et al (2009) Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis doi:101016/​jatherosclerosis​200808026
22.
go back to reference Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD (2005) Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study. Diabetologia 48:370–378PubMedCrossRef Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD (2005) Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes—the EURODIAB Prospective Complications Study. Diabetologia 48:370–378PubMedCrossRef
23.
go back to reference Schram MT, Chaturvedi N, Schalkwijk C et al (2003) Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 26:2165–2173PubMedCrossRef Schram MT, Chaturvedi N, Schalkwijk C et al (2003) Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care 26:2165–2173PubMedCrossRef
24.
go back to reference Schiffrin EL, Lipman ML, Mann JF (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116:85–97PubMedCrossRef Schiffrin EL, Lipman ML, Mann JF (2007) Chronic kidney disease: effects on the cardiovascular system. Circulation 116:85–97PubMedCrossRef
25.
go back to reference Stephenson J, Fuller J (1994) Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 37:278–285CrossRef Stephenson J, Fuller J (1994) Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia 37:278–285CrossRef
26.
go back to reference Chaturvedi N, Sjoelie AK, Porta M et al (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24:284–289PubMedCrossRef Chaturvedi N, Sjoelie AK, Porta M et al (2001) Markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24:284–289PubMedCrossRef
27.
go back to reference Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219–227PubMedCrossRef Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH (2001) Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int 60:219–227PubMedCrossRef
28.
go back to reference Soedamah-Muthu SS, Colhoun HM, Abrahamian H et al (2002) Trends in hypertension management in type I diabetes across Europe, 1989/1990–1997/1999. Diabetologia 45:1362–1371PubMedCrossRef Soedamah-Muthu SS, Colhoun HM, Abrahamian H et al (2002) Trends in hypertension management in type I diabetes across Europe, 1989/1990–1997/1999. Diabetologia 45:1362–1371PubMedCrossRef
29.
go back to reference Schram MT, Schalkwijk CG, Bootsma AH, Fuller JH, Chaturvedi N, Stehouwer CD (2005) Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. Hypertension 46:232–237PubMedCrossRef Schram MT, Schalkwijk CG, Bootsma AH, Fuller JH, Chaturvedi N, Stehouwer CD (2005) Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. Hypertension 46:232–237PubMedCrossRef
30.
go back to reference Chaturvedi N, Schalkwijk CG, Abrahamian H, Fuller JH, Stehouwer CD (2002) Circulating and urinary transforming growth factor beta1, Amadori albumin, and complications of type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 25:2320–2327PubMedCrossRef Chaturvedi N, Schalkwijk CG, Abrahamian H, Fuller JH, Stehouwer CD (2002) Circulating and urinary transforming growth factor beta1, Amadori albumin, and complications of type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 25:2320–2327PubMedCrossRef
31.
go back to reference Soedamah-Muthu SS, Chaturvedi N, Teerlink T, Idzior-Walus B, Fuller JH, Stehouwer CD (2005) Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study. J Intern Med 258:450–459PubMedCrossRef Soedamah-Muthu SS, Chaturvedi N, Teerlink T, Idzior-Walus B, Fuller JH, Stehouwer CD (2005) Plasma homocysteine and microvascular and macrovascular complications in type 1 diabetes: a cross-sectional nested case-control study. J Intern Med 258:450–459PubMedCrossRef
32.
go back to reference Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD (2006) Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 91:129–135PubMedCrossRef Schalkwijk CG, Chaturvedi N, Schram MT, Fuller JH, Stehouwer CD (2006) Adiponectin is inversely associated with renal function in type 1 diabetic patients. J Clin Endocrinol Metab 91:129–135PubMedCrossRef
33.
go back to reference Gruden G, Bruno G, Chaturvedi N et al (2008) Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: a novel circulating marker for diabetic neuropathy. Diabetes 57:1966–1970PubMedCrossRef Gruden G, Bruno G, Chaturvedi N et al (2008) Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: a novel circulating marker for diabetic neuropathy. Diabetes 57:1966–1970PubMedCrossRef
34.
go back to reference Koivisto VA, Stevens LK, Mattock M et al (1996) Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 19:689–697PubMedCrossRef Koivisto VA, Stevens LK, Mattock M et al (1996) Cardiovascular disease and its risk factors in IDDM in Europe. EURODIAB IDDM Complications Study Group. Diabetes Care 19:689–697PubMedCrossRef
35.
go back to reference Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef
36.
go back to reference Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK (1995) Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 38:437–444PubMedCrossRef Aldington SJ, Kohner EM, Meuer S, Klein R, Sjolie AK (1995) Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 38:437–444PubMedCrossRef
37.
go back to reference Fossati P, Prencipe L (1982) Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 28:2077–2080PubMed Fossati P, Prencipe L (1982) Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. Clin Chem 28:2077–2080PubMed
38.
go back to reference Sugiuchi H, Uji Y, Okabe H et al (1995) Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 41:717–723PubMed Sugiuchi H, Uji Y, Okabe H et al (1995) Direct measurement of high-density lipoprotein cholesterol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 41:717–723PubMed
39.
go back to reference Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499–502PubMed
40.
go back to reference Smulders RA, Stehouwer CD, Schalkwijk CG, Donker AJ, van Hinsbergh VW, TeKoppele JM (1998) Distinct associations of HbA1c and the urinary excretion of pentosidine, an advanced glycosylation end-product, with markers of endothelial function in insulin-dependent diabetes mellitus. Thromb Haemost 80:52–57PubMed Smulders RA, Stehouwer CD, Schalkwijk CG, Donker AJ, van Hinsbergh VW, TeKoppele JM (1998) Distinct associations of HbA1c and the urinary excretion of pentosidine, an advanced glycosylation end-product, with markers of endothelial function in insulin-dependent diabetes mellitus. Thromb Haemost 80:52–57PubMed
41.
go back to reference Lieuw-A-Fa ML, van Hinsbergh VW, Teerlink T et al (2004) Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction. Nephrol Dial Transplant 19:631–636PubMedCrossRef Lieuw-A-Fa ML, van Hinsbergh VW, Teerlink T et al (2004) Increased levels of N(epsilon)-(carboxymethyl)lysine and N(epsilon)-(carboxyethyl)lysine in type 1 diabetic patients with impaired renal function: correlation with markers of endothelial dysfunction. Nephrol Dial Transplant 19:631–636PubMedCrossRef
42.
go back to reference Koyama Y, Takeishi Y, Niizeki T et al (2008) Soluble receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J Card Fail 14:133–139PubMedCrossRef Koyama Y, Takeishi Y, Niizeki T et al (2008) Soluble receptor for advanced glycation end products (RAGE) is a prognostic factor for heart failure. J Card Fail 14:133–139PubMedCrossRef
43.
go back to reference Falcone C, Emanuele E, D’Angelo A et al (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25:1032–1037PubMedCrossRef Falcone C, Emanuele E, D’Angelo A et al (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25:1032–1037PubMedCrossRef
44.
go back to reference Humpert PM, Kopf S, Djuric Z et al (2006) Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care 29:1111–1113PubMedCrossRef Humpert PM, Kopf S, Djuric Z et al (2006) Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes. Diabetes Care 29:1111–1113PubMedCrossRef
45.
go back to reference Nakamura K, Yamagishi S, Adachi H et al (2007) Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 13:185–189PubMedCrossRef Nakamura K, Yamagishi S, Adachi H et al (2007) Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes. Mol Med 13:185–189PubMedCrossRef
46.
go back to reference Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275:25781–25790PubMedCrossRef Tanaka N, Yonekura H, Yamagishi S, Fujimori H, Yamamoto Y, Yamamoto H (2000) The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. J Biol Chem 275:25781–25790PubMedCrossRef
47.
go back to reference Miura J, Yamamoto Y, Osawa M et al (2007) Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol 27:253–254PubMedCrossRef Miura J, Yamamoto Y, Osawa M et al (2007) Endogenous secretory receptor for advanced glycation endproducts levels are correlated with serum pentosidine and CML in patients with type 1 diabetes. Arterioscler Thromb Vasc Biol 27:253–254PubMedCrossRef
48.
go back to reference Yamagishi S, Adachi H, Nakamura K et al (2006) Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55:1227–1231PubMedCrossRef Yamagishi S, Adachi H, Nakamura K et al (2006) Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55:1227–1231PubMedCrossRef
49.
go back to reference Semba RD, Ferrucci L, Fink JC et al (2009) Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 53:51–58PubMedCrossRef Semba RD, Ferrucci L, Fink JC et al (2009) Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 53:51–58PubMedCrossRef
50.
go back to reference Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G (2005) Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62:37–43CrossRef Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G (2005) Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62:37–43CrossRef
Metadata
Title
Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study
Authors
J. W. M. Nin
I. Ferreira
C. G. Schalkwijk
M. H. Prins
N. Chaturvedi
J. H. Fuller
C. D. A. Stehouwer
EURODIAB Prospective Complications Study Group
Publication date
01-04-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 4/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1263-5

Other articles of this Issue 4/2009

Diabetologia 4/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.